RxDoctor Payments Data

Navjot Rakkar, MD

Internal Medicine · Surprise, AZNPI 1598714263

Payments from drug & device makers

$1,776in general payments, 2019–2025

Across 104 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$380
  • Novo Nordisk$181
  • AbbVie$163
  • Philips North America LLC$151
  • GSK$115
  • Lilly USA, LLC$92
  • plus $694 from 19 others

What the payments were for

  • Food & beverage$1,776100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,776 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$149,320
Medicare patients
439
Services billed
1,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$119,550
MounjaroTirzepatide80$103,926
JardianceEmpagliflozin59$85,222
OzempicSemaglutide63$60,654
JanuviaSitagliptin Phosphate50$56,702
FarxigaDapagliflozin Propanediol43$47,609
XareltoRivaroxaban37$33,549
RybelsusSemaglutide12$29,072
MyrbetriqMirabegron33$23,741
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$16,856
Tresiba Flextouch U-200Insulin Degludec22$16,824
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,698
BelsomraSuvorexant22$10,407
Levothyroxine Sodium694$7,120
MotegrityPrucalopride Succinate12$6,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$81$123,611135 claims
Lilly USA, LLCMounjaro$92$103,92680 claims
Novo NordiskOzempic, Rybelsus$181$89,72775 claims
Boehringer IngelheimJardiance$87$85,22259 claims
MerckJanuvia, Belsomra$13$67,10972 claims
AstraZenecaFarxiga, Breztri Aerosphere$380$63,30767 claims
Johnson & JohnsonXarelto$44$33,54937 claims
GSKTrelegy Ellipta, Arnuity Ellipta$115$20,49225 claims
AbbVieSynthroid$163$2,39140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →